Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTMarketBeatThu, August 6, 2026 at 3:03 AM GMT+2 6 min readKey PointsInterested in Evolus, Inc.? Here are five stocks we like better.Strong second-quarter performance: Evolus reported 21% revenue growth to $84.1 million and its third consecutive quarter of positive adjusted EBITDA at $4.7 million, driven by gains in neurotoxins, injectable gels and customer adoption.Raised 2026 outlook: The company increased the lower end of its revenue forecast to $330 million, maintained the $337 million upper end, raised adjusted gross-margin guidance to 67.0%-67.5% and reaffirmed its low- to mid-single-digit adjusted EBITDA margin target.Portfolio and international expansion: Evolus is broadening its aesthetics offering through the Profhilo U.S. agreement, upcoming Evolysse products and expanded rights in Canada, Australia and New Zealand, while targeting more than $100 million in peak annual Profhilo revenue and launches in several markets through 2028.Evolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations.Global net revenue totaled $84.1 million in the second quarter, including $75.2 million in toxin revenue and $8.9 million from injectable hyaluronic acid gels. The company generated adjusted EBITDA of $4.7 million, its third consecutive quarter of positive adjusted EBITDA, according to Chief Financial Officer Tatjana Mitchell.→